Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Avenue Capital Group

PharmaDeviceNews Avenue Capital Group

Representative image: Citius Oncology’s Lymphir commercialisation push highlights the growing pressure on rare cancer biotech firms to turn FDA approvals and fresh funding into real-world treatment adoption.

Pharma & Biotech

Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?

by Pallavi Madhiraju
May 9, 2026
0 Comments

Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.

Read More

Latest news and features

LB-102 pivotal trial accelerates as LB Pharmaceuticals expands psychiatric pipeline
FDA endorsement moves once-weekly sutacimig into decisive Glanzmann thrombasthenia study
SEP-479 clears first pharmacokinetic hurdle in pursuit of oral hypoparathyroidism therapy
Tenax heart failure drug fails Phase 3 test despite 49% drop in cardiac stress biomarker
NCX 470 moves toward China approval with U.S. review already underway
Quantum BioPharma gets FDA clearance to advance Lucid-MS into Phase 2 progressive multiple sclerosis trial
Labcorp gets FDA approval for PGDx elio tissue complete CDx in BRAF-mutated melanoma
Why Almirall’s latest China biotech deal could open a new small-molecule route into dermatology
What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3
MindMaze Therapeutics has finished its portfolio reset, but why is half of the CHF 8m Neuro.io financing still pending?
Akeso is betting a dual-target ADC can break through breast cancer’s increasingly crowded treatment field
HanchorBio wants biomarkers to sharpen its cancer pipeline. Can Taiwan Cancer Moonshot data deliver?

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Kratos raises 2026 revenue guidance as hypersonics, drones and propulsion demand accelerate
ADNOC Gas commits $13.2bn to Rich Gas Development as 60% EBITDA target meets Hormuz risk
Cineplex revenue hits record C$383.7m as moviegoers return, but shares fall
Nearly three-quarters of England enters drought as water restrictions spread during fifth heatwave
Colombia earthquake death toll reaches 224 as rescuers search for thousands missing

TAGS

clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immuno-oncology immunotherapy Inc. Johnson & Johnson medical devices oncology precision oncology rare disease U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.